Press release | Gothenburg May 26th 2021 | Texray AB announces that Vinnova grants Texray funding for competence enhancement through external expertise, with the Medtech4Health strategic funding program. Texray strives to improve the working environment for healthcare professionals exposed to X-ray in the Operating Room. The growing global demand for ergonomic, sustainable, and validated personal protection equipment (PPE) confirms the inevitable need for continuous product development.

"We are thrilled to receive yet another grant from Vinnova. The grant allows us to broaden our internal competencies while also performing a clinical evaluation of MindPeace as a follow-up to the phantom study we recently completed," says Petra Apell, Founder at Texray.

 

The evaluation will be performed in different clinical settings in European-based hospitals with teams from various medical specialties such as; interventional cardiology, vascular surgery, and interventional radiology.

About Vinnova

Vinnova is the Swedish governmental agency for innovation systems with the mission to boost sustainable growth. This is primarily executed by funding innovation and research-related projects.

About Medtech4Health

Medtech4Health is a national Strategic Innovation Program within medical technology with a focus to implementing medical technologies to streamline healthcare and strengthen the medical technology industry, nationally and internationally. To make this possible, they bring together stakeholders in healthcare, academia, and business in different projects.

🟡

About Texray

Texray has developed and patented the first radiation protection textile to address the need for comfortable personal protection equipment (PPE). It is currently used in products designed for medical practitioners using X-ray in surgical interventions. Texray may also provide value for professionals in various other industry sectors, including aeronautics, first response, veterinary medicine, and dental.

For more information, please contact Petra Apell